EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Part of paid clinical trials in Tampa, Florida.
- Sponsor
- Eclipse Life Sciences, Inc.
- Study ID
- NCT06536491
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- EC-104 high dose — DRUGIntravitreal injection
- EC-104 low dose — DRUGIntravitreal injection
- Dexamethasone intravitreal implant — DRUGMarketed product intravitreal injection
Study Details
This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated with locally administered corticosteroids without a clinically significant rise in intraocular pressure (IOP).
Key Dates
- Start date
- Aug 19, 2024
- Status verified
- Jan 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 75 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: EC-104 high doseIntravitreal implant of fluocinolone acetonide
- Experimental: EC-104 low doseIntravitreal implant of fluocinolone acetonide
- Active Comparator: Dexamethasone intravitreal implantMarketed product
Primary Outcome Measure
Ocular and Systemic Safety [ Time Frame: Through Week 24 ]
Central Contacts
- Freddie Batalla, MBA919-443-5542
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Retina Associates of Florida, LLC | Tampa | Florida | 33609 | Cindy Lopez |
Find similar trials in Tampa, FL
By condition
By specialty
By research site
Related Studies
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)PHASE1 · Recruiting · Ocugen · Deerfield Beach, Florida
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)PHASE1 · Recruiting · Genentech, Inc. · Peoria, Arizona
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Gilbert, Arizona
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Bakersfield, California